Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study.
Journal of neurology
confidence
Key findings
Creatine monohydrate was well tolerated but did not improve muscle strength or daily-life activities in DM1 patients vs placebo.
View source on PubMed (PMID 12529796) ↗
- Sample size
- 34 patients
- Population
- Patients with defined myotonic dystrophy type 1 (DM1)
- Dosing
- 10.6 g/day days 1-10, then 5.3 g/day days 11-56
- Duration
- 8 weeks per treatment phase (cross-over)
- Route
- oral
- Blinding
- double_blind
- Controls
- placebo
- Drug class
- nootropic
Measured endpoints
- manual and quantitative muscle strengthNo changemusculoskeletalnot_significant
- daily-life activitiesNo changeothernot_significant
- patients' own global assessmentNo changeothernot_significant
- tolerability/side effectsNo changesafetynot_reported
Full abstract
We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1-10, 5.3 g day 11-56) in one of 2 treatment sequences. There was no significant improvement using manual and quantitative muscle strength, daily-life activities, and patients' own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.